Gaginella T S, Bauman J H
Drug Intell Clin Pharm. 1983 Dec;17(12):873-85. doi: 10.1177/106002808301701201.
Ranitidine is a selective, competitive histamine H2-receptor antagonist recently approved by the Food and Drug Administration for use in the short-term treatment of active duodenal ulcers and gastric hypersecretory conditions. Ranitidine is four to ten times more potent than cimetidine on a molar basis in inhibiting stimulated gastric acid secretion. Clinical studies have demonstrated that ranitidine is as effective as cimetidine and is similarly well tolerated. Based on available literature (approximately 700 publications), this article reviews the pharmacology, safety profile, and clinical efficacy of ranitidine in duodenal ulcers and gastric hypersecretory conditions.
雷尼替丁是一种选择性、竞争性组胺H2受体拮抗剂，最近已获美国食品药品监督管理局批准，用于短期治疗活动性十二指肠溃疡和胃酸分泌过多症。在抑制刺激后的胃酸分泌方面，雷尼替丁的摩尔效力比西咪替丁强4至10倍。临床研究表明，雷尼替丁与西咪替丁疗效相当，且耐受性相似。基于现有文献（约700篇出版物），本文综述了雷尼替丁在十二指肠溃疡和胃酸分泌过多症中的药理学、安全性和临床疗效。
